Cell proliferation activity unrelated to COX-2 expression in ovarian tumors

International Journal of Gynecological Cancer

Volumn 17, Issue 3, 2007, Pages 607-614

  Yoshida, A ^a   Sarian, L O ^a   Andrade, L A L A ^a   Pignataro, F ^a   Pinto, G A ^a   Derchain, S F M ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Borderline ovarian tumors; Cell proliferation; Cyclooxygenase; Immunohistochemistry; Ovarian cancer

Indexed keywords

CYCLOOXYGENASE 2; KI 67 ANTIGEN;

ADENOMA; ADULT; ARTICLE; BENIGN TUMOR; CARCINOGENESIS; CELL ACTIVITY; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; EPITHELIUM TUMOR; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LAPAROTOMY; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MUCINOUS CARCINOMA; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 34248331275     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.00838.x     Document Type: Article

References (33)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin 2005 55:74 108.
2. Scott M, McCluggage WG. Current concept in ovarian epithelial tumorigenesis: correlation between morphological and molecular data. Histol Histopathol 2006 21:81 92.
3. Shih I-M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004 164:1511 8.
4. Sirois J, Sayasith K, Brown KA, Stock AE, Bouchard N, Doré M. Cyclooxygenase-2 and its role in ovulation: a 2004 account. Hum Reprod Update 2004 10:373 85.
5. Doré M, Côté LC, Mitchell A, Sirois J. Expression of prostaglandin G/H synthase type 1, but not type 2, in human ovarian adenocarcinomas. J Histochem Cytochem 1998 46:77 84.
6. Mao JT, Cui X, Reckamp K et al. Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer. Clin Lung Cancer 2005 7:30 9.
7. Choe MS, Zhang X, Shin HJ, Shin DM, Chen ZG. Interaction between epidermal growth factor receptor and cyclooxygenase-2 mediated pathways and its implications for the chemoprevention of head and neck cancer. Mol Cancer Ther 2005 4:1448 55.
8. Alrawi SJ, Schiff M, Carroll RE et al. Aberrant crypt foci. Anticancer Res 2006 26:107 19.
9. Gallicchio L, McSorley MA, Newschaffer CJ et al. Nonsteroidal anti-inflammatory drugs, cyclooxygenase polymorphisms, and the risk of developing breast carcinoma among women with benign breast disease. Cancer 2006 106:1443 52.
10. Dursun P, Gultekin M, Yuce K, Ayhan A. Lower expression of cyclooxygenase-2: is it associated with development of borderline ovarian tumors? Med Hypotheses 2005 64:273 8.
11. Li S, Miner K, Fannin R, Barrett JC, Davis BJ. Cyclooxygenase-1 and 2 in normal and malignant human ovarian epithelium. Gynecol Oncol 2004 92:622 7.
12. Ferrandina G, Raneletti FO, Lauriola L et al. Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer. Gynecol Oncol 2002 85:305 10.
13. Fujimoto J, Toyoki H, Sakaguchi H, Jahan I, Alam SM, Tamaya T. Clinical implications of expression of cyclooxygenase-2 related to angiogenesisi in ovarian cancer. Oncol Rep 2006 15:21 5.
14. Matsumoto Y, Ishiko O, Deguchi M, Nakagawa E, Ogita S. Cyclooxygenase-2 expression in normal ovaries and epithelial neoplasms. Int J Mol Med 2001 8:31 6.
15. Kaern J, Aghmesheh M, Nesland JM et al. Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors? Int J Gynecol Cancer 2005 15:1014 22.
16. Kritpracha K, Hanprasertpong J, Chandeying V, Dechsukhum C, Geater A. A survival analysis in advanced epithelial ovarian carcinoma in relation to proliferative index of MIB-1 immunostaining. J Obstet Gynaecol Res 2005 31:268 76.
17. Remmele W, Schicketanz KH. Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs subjective grading (IRS). Pathol Res Pract 1993 189:862 6.
18. R Development Core Team. R: A language and environment for statistical computing. R Foundation for statistical computing, Vienna, Austria, 2004. Available at:http://www.R-project.org.
19. FIGO Cancer Committee. Staging announcement. Gynecol Oncol 1986 25:383 5.
20. Ferrandina G, Zannoni GF, Ranelletti FO et al. Cyclooxygenase-2 expression in borderline in ovarian tumors. Gynecol Oncol 2004 95:46 51.
21. Seo SS, Song YS, Kang D et al. Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer. Gynecol Oncol 2004 92:927 35.
22. Kinoshita T, Takahashi Y, Sakashita T, Inoue H, Tanabe T, Yoshimoto T. Growth stimulation and induction of epidermal growth factor receptor by overexpression of cyclooxygenase 1 and 2 in human colon carcinoma cells. Biochim Biophys Acta 1999 1438:120 30.
23. Coffey RJ, Hawkey CJ, Damstrup L et al. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci USA 1997 94:657 62.
24. Kurman RJ, Seidman JD, Shih I-M. Serous borderline tumors of the ovary. Histopathology 2005 47:310 8.
25. Rodríguez IM, Prat J. Mucinous tumors of the ovary. A clinicalpathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas. Am J Surg Pathol 2002 26:139 52.
26. Hess V, A'Hern R, Nasiri N et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol 2004 22:1040 4.
27. Schlosshauer PW, Cohen CJ, Llorca FP et al. Prophylactic oophorectomy a morphologic and immunohistochemical study. Cancer 2003 98:2599 606.
28. Ali-Fehmi R, Che M, Khalifeh I et al. The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma. Cancer 2003 98:1423 9.
29. Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ, Ronnett BM. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 2004 23:41 4.
30. Khalifeh I, Munkarah AR, Lonardo F et al. Expression of COX-2, CD 34, Bcl-2 and p 53 and survival in patients with primary peritoneal serous carcinoma and primary ovarian serous carcinoma. Int J Gynecol Pathol 2004 23:162 9.
31. Munkarah A, Ali-Fehmi R. COX-2: a protein with an active role in gynecological cancers. Curr Opin Obstet Gynecol 2005 17:49 53.
32. Rigas B, Kashfi K. Cancer prevention: a new era beyond cyclooxygenase-2. J Pharmacol Exp Ther 2005 314:1 8.
33. Kashfi K, Rigas B. Is COX-2 a "collateral" target in cancer prevention? Biochem Soc Trans 2005 33:724 7.